RMD:NYE-ResMed Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 213.25

Change

+5.21 (+2.50)%

Market Cap

USD 8.15B

Volume

0.99M

Analyst Target

USD 184.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-31 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

N/A

USD 67.25B
ALC Alcon AG

N/A

USD 46.69B
BAX Baxter International Inc

N/A

USD 19.88B
AVTR Avantor Inc

N/A

USD 17.36B
TFX Teleflex Incorporated

N/A

USD 11.55B
ATR AptarGroup Inc

N/A

USD 10.12B
STVN Stevanato Group SpA

N/A

USD 5.97B
BLCO Bausch + Lomb Corp

N/A

USD 5.61B
WRBY Warby Parker Inc

N/A

USD 1.79B
INFU InfuSystems Holdings Inc

N/A

USD 0.14B

ETFs Containing RMD

EKG First Trust Nasdaq Lux Di.. 10.77 % 0.00 %

N/A

USD 2.52M
EDOC:AU BetaShares Digital Health.. 8.18 % 0.00 %

N/A

N/A
FDOC:LSE Fidelity Digital Health U.. 5.20 % 0.00 %

N/A

USD 2.95M
FDHT 5.13 % 0.00 %

N/A

N/A
EDOC:LSE Global X Telemedicine & D.. 4.99 % 0.00 %

N/A

USD 3.76M
EDOG:LSE Global X Telemedicine & D.. 4.99 % 0.00 %

N/A

USD 0.23M
MCSE Martin Currie Sustainable.. 4.88 % 0.00 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 4.52 % 0.00 %

N/A

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.52 % 0.00 %

N/A

USD 4.62M
EDOC:SW Global X Telemedicine & D.. 4.25 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.19 % 0.00 %

N/A

N/A
ENTR ERShares Entrepreneurs ET.. 3.79 % 0.49 %

N/A

USD 0.08B
FAIR:AU BetaShares Australian Sus.. 3.27 % 0.00 %

N/A

USD 1.50B
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.36 % 0.00 %

N/A

N/A
EX20:AU BetaShares Australian Ex-.. 2.34 % 0.00 %

N/A

USD 0.27B
HLTH:AU VanEck Global Healthcare .. 2.32 % 0.00 %

N/A

USD 0.06B
JKH 0.00 % 0.30 %

N/A

N/A
RISN Inspire Tactical Balanced.. 0.00 % 0.00 %

N/A

USD 0.09B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.04B
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

N/A

N/A
VCAV:XETRA VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 0.01B
CVGB:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 2.24M
CAVE:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

N/A
CAVE:SW VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.97% 94% A 90% A-
Dividend Return 0.56% 44% F 12% F
Total Return 24.53% 94% A 89% A-
Trailing 12 Months  
Capital Gain -4.01% 47% F 22% F
Dividend Return 0.86% 44% F 10% F
Total Return -3.14% 47% F 19% F
Trailing 5 Years  
Capital Gain 63.69% 79% B- 78% C+
Dividend Return 6.51% 71% C- 21% F
Total Return 70.19% 79% B- 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 6.34% 61% D- 62% D
Dividend Return 7.18% 61% D- 58% F
Total Return 0.84% 44% F 19% F
Risk Return Profile  
Volatility (Standard Deviation) 26.43% 67% D+ 38% F
Risk Adjusted Return 27.17% 67% D+ 49% F
Market Capitalization 8.15B 85% B 93% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.70 89% 24%
Price/Book Ratio 6.10 8% 15%
Price / Cash Flow Ratio 41.75 15% 6%
Price/Free Cash Flow Ratio 19.94 17% 15%
Management Effectiveness  
Return on Equity 22.39% 100% 87%
Return on Invested Capital 19.12% 100% 88%
Return on Assets 11.91% 100% 95%
Debt to Equity Ratio 34.66% 55% 69%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.